Payment overview · 2025
General Payments
$474.92
28 reported records · 10 companies
Healthcare provider profile · identity verified
Daniel Evan Boykin, DO
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1194380659
Verified facts
What the public records show
CMS Open Payments records show Daniel Evan Boykin, DO received $474.92 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.62 | 22.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.37 | 19.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.40 | 16.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.20 | 14.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.29 | 6.2% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.24 | 6.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.10 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.83 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.88 | 3.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.99 | 2.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.92 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.06 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.83 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.83 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.94 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.79 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.99 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 177 |
| Losartan Potassium | Losartan Potassium | 420 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 89 |
| Lisinopril | Lisinopril | 218 | 85 |
| Alprazolam | Alprazolam | 207 | 47 |
| Omeprazole | Omeprazole | 207 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 61 |
| Gabapentin | Gabapentin | 146 | 60 |
| Meloxicam | Meloxicam | 144 | 61 |
| Ozempic | Semaglutide | 140 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 44 |
| Mounjaro | Tirzepatide | 127 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 43 |
| Clonazepam | Clonazepam | 117 | 23 |
| Trazodone Hcl | Trazodone Hcl | 117 | 42 |
| Tramadol Hcl | Tramadol Hcl | 109 | 36 |
| Metformin Hcl Er | Metformin Hcl | 106 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 31 |
| Montelukast Sodium | Montelukast Sodium | 100 | 43 |
| Simvastatin | Simvastatin | 98 | 37 |
| Metformin Hcl | Metformin Hcl | 90 | 40 |
| Glipizide Er | Glipizide | 87 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 77 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 33 |
| Famotidine | Famotidine | 74 | 28 |
| Furosemide | Furosemide | 74 | 39 |
| Jardiance | Empagliflozin | 74 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 27 |
| Allopurinol | Allopurinol | 71 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 27 |
| Chlorthalidone | Chlorthalidone | 64 | 29 |
| Carvedilol | Carvedilol | 60 | 18 |
| Eliquis | Apixaban | 60 | 22 |
| Celecoxib | Celecoxib | 58 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 24 |
| Bupropion Xl | Bupropion Hcl | 56 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 24 |
| Propranolol Hcl | Propranolol Hcl | 56 | 13 |
| Sertraline Hcl | Sertraline Hcl | 55 | 22 |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Atenolol | Atenolol | 50 | 19 |
| Spironolactone | Spironolactone | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 17 |
| Irbesartan | Irbesartan | 44 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 13 |
| Prednisone | Prednisone | 40 | 37 |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Glimepiride | Glimepiride | 37 | 12 |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Lorazepam | Lorazepam | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 19 |
| Topiramate | Topiramate | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 13 |
| Valsartan | Valsartan | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Modafinil | Modafinil | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.92 · 28 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, INJECTAFER, Korlym, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error